Invert Graphite Limited has released a press release.
Half Year Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Invert Graphite Limited on 6ix
Earlier from Invert Graphite
- Appendix 4C - December 2016 quarter
- Phase II Clinical Trial - First Patient In
- Collaboration and IP option agreement with Monash University
- FDA - lift of clincial hold
- Submission of IND amendments for Phase II study
Later from Invert Graphite
- Phase II clinical trial progress update
- Appendix 4C
- Appointment of Dr. Rosalind Wilson as CEO
- Appendix 4C - quarterly
- Appendix 4E and Full Year Statutory Accounts
Follow Invert Graphite into a list and get an email when it puts out news.
Follow Invert Graphite